Meanwhile, the S&P BSE Sensex was up 82.10 points or 0.33% at 24,728.58.

On BSE, so far 6,885 shares were traded in the counter as against average daily volume of 21,416 shares in the past one quarter. The stock hit a high of Rs 1,448.80 and low of Rs 1,420 so far during the day. The stock had hit a record high of Rs 1,720 on 12 August 2015. The stock had hit a 52-week low of Rs 1,090 on 23 March 2015. The stock had outperformed the market over the past one month till 4 March 2016, rising 8.26% compared with Sensex's 1.27% gains. The scrip had also outperformed the market in past one quarter, rising 4.46% as against Sensex's 3.87% fall.

The large-cap company has equity capital of Rs 17.60 crore. Face value per share is Rs 2.

Ajanta Pharma said that it has received final approval from the United States Food and Drug Administration for Almotriptan Malate Tablets (6.25 mg & 12.5 mg), a generic version of Axert, which is used for treatment of acute migraine pain. The company's wholly owned US subsidiary, Ajanta Pharma USA Inc. is scheduled to launch Almotriptan Tablets in US shortly, the company said.

Ajanta Pharma's consolidated net profit rose 19.6% to Rs 111.30 crore on 16% growth in net sales to Rs 465.71 crore in Q3 December 2015 over Q3 December 2014.

Ajanta Pharma is an established pharmaceutical formulation company with clear focus on fast growing therapeutic segments of aardiology, ophthalmology, dermatology and pain management in the Indian market and is among the fastest growing in the country.